In this episode, Sarah Court and Laurel Beversdorf begin a two-part investigation into Louisa Nicola and the rapidly growing industry built around Alzheimer's prevention, brain optimization, and women's brain health. They examine how legitimate scientific concerns about dementia become transformed into highly marketable narratives, and explain the difference between what current evidence supports and what many online health personalities confidently claim.
Sarah and Laurel break down the strongest evidence on dementia prevention, including findings from the 2024 Lancet Commission, and discuss what is known about exercise, vascular health, hearing, vision, education, social connection, and other modifiable risk factors. They also introduce concepts they call mechanism theater, evidence cosplay, and the fear-to-action marketing pipeline, showing how preliminary research is often stretched into certainty to sell protocols, supplements, and personal brands. Along the way, they critically examine several of Nicola's most common claims—including that Alzheimer's starts in your 30s, that women face six times the risk, and that heavy resistance training is uniquely protective—and compare those claims with the available evidence.
Part 2 of this series will continue the investigation into Louisa Nicola's recommendations, products, and marketing strategies.
SIGN UP FOR THE INTEREST LIST for Lift for Longevity
FREE Barbell Mini Course when you get on our mailing list
FOLLOW Movement Logic on Instagram
WATCH Movement Logic on YouTube
LEARN MORE on the Movement Logic website
Foldable Home Barbell Rack by Verse, coupon code MovementLogic10%OFF at checkout
RESOURCES
113: Debunking Menopause Grifters: Dr Mary Claire Haver and Dr. Vonda Wright
111: Make Stacy Sims Make Sense
The Lancet Commission: Dementia Prevention, Intervention, and Care: 2024 Report
Alzheimer's Association 2025 Fact Sheet
Neuro Athletics
Narrative review on resistance training and Alzheimer's disease (co-authored by Louisa Nicola)
Dr. Vonda Wright podcast featuring Louisa Nicola
The Diary of a CEO podcast featuring Louisa Nicola
APOE4 and Alzheimer's disease research
New England Journal of Medicine (2024) biomarker study on preclinical Alzheimer's disease
